

**IN THE CLAIMS:**

1. (Amended) A composition based on plant extracts, with an anti-oxidant activity which is particularly useful in the prevention and treatment of circulation problems and in the prevention and treatment of adiposity, characterized for the treatment of adiposity and cellulitis in humans, wherein said composition comprises: in that its active ingredients comprise, in association,  
biflavones of *Ginkgo biloba*,  
catechine and/or epicatechine,  
cumarine or derivatives thereof,  
iodine, and  
a component chosen from among madecassic acid, asiatic acid, asiaticoside and mixtures of these.
2. (Amended) A composition according to Claim 1, ~~characterised in that it~~ wherein said composition is obtained by mixing plant extracts, ~~containing the aforesaid active principles.~~
3. (Amended) A composition according to Claim 2, ~~characterised in that the~~ wherein said extracts are in phytosomal form.
4. (Amended) A composition according to ~~any one of the preceding Claims,~~ claim 1 wherein said composition further includes flavonol glucosides and lactonic terpenes.
5. (Amended) A composition according to ~~any Claim from 1 to 4, characterised in that~~ it claim 1 wherein said composition also includes ~~an active principle~~ a compound chosen from the group consisting of methylxanthinic derivatives, chlorogenic acids, mono- and di-

caffeoylchinic acid and derivatives thereof, eicosapentaenoic acid, docohexaenoic acid, gamma-linolenic acid and mixtures thereof.

6. (Amended) A composition according to ~~any of Claims 1 to 4, characterised in that it~~  
claim 1 wherein said composition is obtained by mixing plant extracts in the following percentages by weight:

1.5-32% of *Ginkgo biloba* biflavone extract;

6-80% of leucocyanidine;

1.5-32% of *Melilotus* and/or *Aesculus hyppocastanum* extract;

1.5-32% of centella extract;

1.5-85% extract of *Fucus vesiculosus*; ~~and optionally~~

~~1.5-32% of standardised *Ginkgo biloba* extract containing flavone glucosides and lactic terpenes.~~

7. (Amended) A composition according to Claim 6, ~~characterised in that with~~  
~~reference to 100 parts of the basic mixture of Claim 6, it also includes one or more of the~~  
following components further comprising one or more of the following relative to 100 parts  
of said composition:

from 1.5 to 32% by weight of *Ilex paraguariensis* extract;

from 1.5 to 32% by weight of artichoke extract;

from 5 to 80% by weight of fish oil; and

from 30 to 120% by weight of borage oil.

8. (Amended) A composition according to ~~any one of the preceding Claims~~ claim 1  
which includes:

0.12-12%, ~~preferably 0.5-6%~~ by weight [[,]] of total biflavones;

0.2-12%, ~~preferably 0.5-8%~~ by weight [[,]] of catechine and/or epicatechine;

0.15-7%, ~~preferably 0.3-3.5%~~ by weight [[,]] of coumarin and derivatives thereof;

0.25-15%, ~~preferably 0.5-7.5%~~ by weight of asiaticoside;

0.25-22%, ~~preferably 0.5-11%~~ by weight ~~[[,]]~~ of asiatic acid and/or madecassic acid;  
and

up to 0.5% of iodine, ~~and, optionally~~

~~0.25-12%, preferably 0.5-6% by weight, of flavonol glucosides and~~

~~0.1-2%, preferably 0.2-1% by weight, of lactonic terpenes.~~

9. (Amended) A composition according to Claim 8, ~~characterised in that it also~~  
~~includes~~ further comprising one or more of the following components:

from 0.05 to 2.5%, ~~preferably 0.1-1%~~ by weight ~~[[,]]~~ of caffeine;

from 0.05 to 4.8%, ~~preferably 0.1-2.5%~~ by weight ~~[[,]]~~ of caffeilchinic acids;

from 0.75 to 24%, ~~preferably 1.5-12%~~ by weight ~~[[,]]~~ of eicosapentaenoic acid;

from 0.6 to 8%, ~~preferably 1.2-4%~~ by weight ~~[[,]]~~ of docoesaenoic acid; and

from 2.5 to 22%, ~~preferably from 5 to 11%~~ by weight of gamma-linolenic acid.

10. (Amended) A composition according to ~~any one of the preceding Claims~~ claim 1 in  
a pharmaceutical form suitable for oral administration to a human.

11. (Cancelled)

12. (New) A composition according to claim 6 further comprising 1.5-32 wt% of  
standardised *Ginkgo biloba* extract containing flavone glucosides and lactonic terpenes.

13. (New) A composition according to claim 8 which comprises:

0.5-6% by weight of total biflavones;

0.5-8% by weight of catechine and/or epicatechine;

0.3-3.5% by weight of coumarin and derivatives thereof;

0.5-7.5% by weight of asiaticoside; and

0.5-11% by weight of asiatic acid and/or madecassic acid.

14. (New) A composition according to claim 8 which further comprises:  
0.25-12% by weight of flavonol glucosides and  
0.1-2% by weight of lactonic terpenes.
15. (New) A composition according to claim 14 comprising:  
0.5-6% by weight of flavonol glucosides, and  
0.2-1% by weight, of lactonic terpenes.
16. (New) A composition according to claim 9 comprising:  
0.1-1% by weight of caffeine;  
0.1-2.5% by weight of caffeilchinic acids;  
1.5-12% by weight of eicosapentaenoic acid;  
1.2-4% by weight of docoesaenoic acid; and  
5 to 11% by weight of gamma-linolenic acid.
17. (New) A method for treating adiposity and cellulites in a human with steps that  
comprise administering to a human suffering from adiposity or cellulitis an effective amount  
of a composition comprising a flavone dimer.
18. (New) A method according to claim 17 wherein said flavone dimer is a biflavone  
extract of *Ginkgo biloba*.
19. (New) A method according to claim 18 wherein said biflavone extract comprises  
amentoflavone, bilobetine, isoginkgetine, ginkgetine, or sciadopisitine.
20. (New) A method according to claim 19 wherein said composition further comprises  
a flavonol glucoside or a lactonic terpene.